Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Feng, Rentian ^a   Milcarek, Christine A ^b,c   Xie, Xiang Qun ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

B cells; Cannabinoid receptor 2; IgM; Liands; STAT3

Indexed keywords

4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; IMMUNOGLOBULIN M; INTERLEUKIN 6; PROTEIN BCL 6; RIMONABANT; STAT3 PROTEIN; TRANSCRIPTION FACTOR PAX5; BCL6 PROTEIN, HUMAN; BORNANE DERIVATIVE; CANNABINOID; DNA BINDING PROTEIN; IL6 PROTEIN, HUMAN; INDOLE DERIVATIVE; IODOPRAVADOLINE; PAX5 PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; POLYMERASE CHAIN REACTION; THYMIDINE INCORPORATION ASSAY; WESTERN BLOTTING; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; BORNANES; CANNABINOIDS; CELL LINE; CELL PROLIFERATION; DNA-BINDING PROTEINS; HUMANS; IMMUNOGLOBULIN M; INDOLES; INTERLEUKIN-6; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STAT3 TRANSCRIPTION FACTOR;

EID: 84906926395     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-30     Document Type: Article

References (40)

1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
2. Lunn CA, Reich EP, Bober L: Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets 2006, 10:653-663.
3. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.
4. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A: Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
5. Manera C, Benetti V, Castelli MP, Cavallini T, Lazzarotti S, Pibiri F, Saccomanni G, Tuccinardi T, Vannacci A, Martinelli A, Ferrarini PL: Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J Med Chem 2006, 49:5947-5957.
6. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H: Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008, 68:339-342.
7. Eisenstein TK, Meissler JJ, Wilson Q, Gaughan JP, Adler MW: Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J Neuroimmunol 2007, 189:17-22.
8. Klein TW: Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5:400-411.
9. Ashton JC, Glass M: The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 2007, 5:73-80.
10. Schuehly W, Paredes JM, Kleyer J, Huefner A, Anavi-Goffer S, Raduner S, Altmann KH, Gertsch J: Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem Biol 2011, 18:1053-1064.
11. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I: Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 2006, 103:696-701.
12. Yang P, Wang L, Xie XQ: Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential. Future Med Chem 2012, 4:187-204.
13. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC, Le Fur GL: SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998, 284:644-650.
14. Daaka Y, Friedman H, Klein TW: Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther 1996, 276:776-783.
15. Cabral GA, Griffin-Thomas L: Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 2009, 11:e3.
16. Agudelo M, Newton C, Widen R, Sherwood T, Nong L, Friedman H, Klein TW: Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes. J Neuroimmune Pharmacol 2008, 3:35-42.
17. Bouaboula M, Dussossoy D, Casellas P: Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528 Implications for receptor biological responses. J Biol Chem 1999, 274:20397-20405.
18. Sherwood TA, Nong L, Agudelo M, Newton C, Widen R, Klein TW: Identification of transcription start sites and preferential expression of select CB2 transcripts in mouse and human B lymphocytes. J Neuroimmune Pharmacol 2009, 4:476-488.
19. Kawamoto T, Gohda E, Iji H, Fujiwara M, Yamamoto I: SKW 6.4 cell differentiation induced by interleukin 6 is stimulated by butyrate. Immunopharmacology 1998, 40:119-130.
20. Kishimoto T, Hirano T, Kuritani T, Yamamura Y, Ralph P, Good RA: Induction of IgG production in human B lymphoblastoid cell lines with normal human T cells. Nature 1978, 271:756-758.
21. Goldstein H, Koerholz D, Chesky L, Fan XD, Ambrus JL Jr: Divergent activities of protein kinases in IL-6-induced differentiation of a human B cell line. J Immunol 1990, 145:952-961.
22. Tamura K, Woo J, Bakri MT, Thomson AW: Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells. Immunology 1993, 79:587-593.
23. Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY, Roodman GD, Lentzsch S: SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-(kappa)B activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 2007, 109:2130-2138.
24. Feng R, Li SR, Lu CS, Andreas C, Stolz DB, Mapara MY, Lentzsch S: Targeting the Microtubular Network as a New Antimyeloma Strategy. Mol Cancer Ther 2011, 10:1886-1896.
25. Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, Defrance T: TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol 2007, 178:7779-7786.
26. McClure EA, North CM, Kaminski NE, Goodman JI: Changes in DNA methylation and gene expression during 2,3,7,8-tetrachlorodibenzo-pdioxin-induced suppression of the lipopolysaccharide-stimulated IgM response in splenocytes. Toxicol Sci 2011, 120:339-348.
27. Korholz D, Gerdau S, Enczmann J, Zessack N, Burdach S: Interleukin 6-induced differentiation of a human B cell line into IgM-secreting plasma cells is mediated by c-fos. Eur J Immunol 1992, 22:607-610.
28. Basu S, Ray A, Dittel BN: Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J Immunol 2011, 187:5720-5732.
29. Feng B, Cheng S, Pear WS, Liou HC: NF-κB inhibitor blocks B cell development at two checkpoints. Med Immunol 2004, 3:1.
30. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H: Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293.
31. Rodriguez-Berriguete G, Prieto A, Fraile B, Bouraoui Y, de Bethencourt FR, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M: Relationship between IL-6/ERK and NF-kappaB: a study in normal and pathological human prostate gland. Eur Cytokine Netw 2010, 21:241-250.
32. Marshall AJ, Niiro H, Yun TJ, Clark EA: Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol Rev 2000, 176:30-46.
33. Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, Grote DM, Witzig TE, Fernandez-Zapico ME, Ansell SM: Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 2011, 118:5540-5549.
34. Daeipour M, Kumar G, Amaral MC, Nel AE: Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line, AF-10. J Immunol 1993, 150:4743-4753.
35. Fornek JL, Tygrett LT, Waldschmidt TJ, Poli V, Rickert RC, Kansas GS: Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood 2006, 107:1085-1091.
36. Faris M, Kokot N, Stahl N, Nel AE: Involvement of Stat3 in interleukin-6-induced IgM production in a human B-cell line. Immunology 1997, 90:350-357.
37. Karras JG, McKay RA, Lu T, Pych J, Frank DA, Rothstein TL, Monia BP: STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression. Cell Immunol 2000, 202:124-135.
38. Lin KI, Tunyaplin C, Calame K: Transcriptional regulatory cascades controlling plasma cell differentiation. Immunol Rev 2003, 194:19-28.
39. Bhattacharya S, Conolly RB, Kaminski NE, Thomas RS, Andersen ME, Zhang Q: A bistable switch underlying B-cell differentiation and its disruption by the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci 2010, 115:51-65.
40. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL: Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004, 173:1158-1165.